AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10784384
Drug: Antioxidant supplement
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplement (beta-carotene, lycopene, lutein, canthaxanthin, alpha-tocopherol) without dietary fiber
Trial: 10784384
Drug: Antioxidant supplement
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplement with pectin
Trial: 10784384
Drug: Antioxidant supplement
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplement with guar
Trial: 10784384
Drug: Antioxidant supplement
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplement with cellulose
Trial: 6989687
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 100 mg slow-release tablets (morning or evening dose)
Trial: 6989687
Drug: Diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 50 mg enteric-coated tablets b.i.d.
Trial: 30908338
Drug: Test lens
RxNorm normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test lens with 0.019 mg ketotifen
Trial: 30908338
Drug: Control lens
RxNorm normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control lens with no added drug
Trial: 23570863
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate 800 mg QD for 15 days with OC
Trial: 23570863
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate 1200 mg QD for 15 days with OC
Trial: 23570863
Drug: OC alone
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC alone (30 μg ethinylestradiol and 150 μg levonorgestrel)
Trial: 19906341
Drug: Desvenlafaxine (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine (fixed doses: 50, 100, 200, or 400 mg/d; flexible doses: 100-400 mg/d)
Trial: 17881750
Drug: Repeat doses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat doses of antenatal corticosteroids (11.4 mg of betamethasone, intramuscular injection, repeated weekly if at risk for preterm delivery)
Trial: 17881750
Drug: Repeat doses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat doses of antenatal corticosteroids
Trial: 12548591
Drug: Pamidronate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (90 mg intravenously)
Trial: 11780252
Drug: Polyphenol tablet,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenol tablet, 3 times a day for 2 weeks, followed by 6 weeks of continued use for group B.
Trial: 11780252
Drug: Polyphenol tablet,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenol tablet, after stopping use for 3 weeks.
Trial: 1293241
Drug: SMS 201‐995
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS 201‐995 therapy (100 micrograms t.d.s. for 5 days)
Trial: 6539322
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of 25% albumin solution
Trial: 6539322
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml of 25% albumin solution
Trial: 6539322
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of 0.9% saline
Trial: 6539322
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml of 0.9% saline
Trial: 31014399
Drug: High-dose IFNα
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IFNα
Trial: 25496405
Drug: Rituximab infusion
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab infusion at a weekly dose of 375 mg/m2 for 4 weeks plus oral daily prednisolone
Trial: 21114550
Drug: Cobalt (Co)
RxNorm normalized name: Cobalt
DrugBank: Cobalt (DB14574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobalt (Co) 59mg intramuscular injection diluted in 5ml 0.9% saline solution twice a day
Trial: 21114550
Drug: Control (5ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (5ml 0.9% saline solution intramuscular injection twice a day)
Trial: 18095751
Drug: Mucoadhesive patch
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mucoadhesive patch containing citrus oil and magnesium salts
Trial: 18095751
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution containing benzocaine and compound benzoin tincture
Trial: 15014007
Drug: ACA125 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACA125 vaccine
Trial: 11500526
Drug: Leptin 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin 0.3 mg/kilogram subcutaneously for 6 days
Trial: 8307916
Drug: endoscopic sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: endoscopic sclerotherapy along with ranitidine 300 mg daily
Trial: 3500688
Drug: 5-hydroxytryptophan (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hydroxytryptophan (200 mg, orally)
Trial: 30062794
Drug: Psyllium 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium 7 g t.d.s.
Trial: 27656054
Drug: Conventional apical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional apical preparation (CAP)
Trial: 22747899
Drug: FENO-driven therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FENO-driven therapy
Trial: 8666450
Drug: Transmandibular implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmandibular implant group
Trial: 8666450
Drug: Endosseous implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endosseous implant group
Trial: 1730190
Drug: Cefotaxime 1
RxNorm normalized name: cefotaxime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 1 g i.v. t.i.d.
Trial: 1730190
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g every 24 hr
Trial: 4053132
Drug: Thiazide diuretic-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide diuretic-based antihypertensive therapy regimens
Trial: 31626127
Drug: Rational-Emotive Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rational-Emotive Behavior Therapy (REBT) for 10 weeks with 8 weeks follow-up
Trial: 23934088
Drug: 5% potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% potassium nitrate as a desensitizing agent 30 min before bleaching with 28% hydrogen peroxide activated by LED
Trial: 8639011
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no testosterone treatment)
Trial: 16164657
Drug: Ferumoxytol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferumoxytol (4 doses of 255 mg iron in 2 weeks or 2 doses of 510 mg iron in 1 to 2 weeks)
Trial: 11401916
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g of DFMO
Trial: 11401916
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g of DFMO
Trial: 9462972
Drug: Triflusal treatment
RxNorm normalized name: triflusal
DrugBank: Triflusal (DB08814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triflusal treatment
Trial: 3896411
Drug: Naltrexone 200
RxNorm normalized name: NALTREXONE 200 mg / TRIAMCINOLONE 6.5 mg SUBCUTANEOUS IMPLANT [Naltrexone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 200 mg
Trial: 3896411
Drug: Naltrexone 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 300 mg
Trial: 3896411
Drug: Acetaminophen placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen placebo
Trial: 3896411
Drug: Naltrexone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (all doses combined)
Trial: 29772111
Drug: Human chorionic
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human chorionic gonadotropin (hCG) 5000 IU injections twice weekly
Trial: 29772111
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Clomiphene citrate and hCG (CC + hCG)
Trial: 27578477
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg tiotropium
Trial: 27578477
Drug: 50 μg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg glycopyrronium
Trial: 22817672
Drug: Warmed intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed intraoperative irrigation solutions
Trial: 22817672
Drug: Both preoperative
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both preoperative warming and warmed intraoperative irrigation solutions
Trial: 20405054
Drug: Doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg/day) alone for 6 weeks
Trial: 20405054
Drug: Doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg/day) + Ivermectin (150 microg/kg) at +4 months
Trial: 15964448
Drug: Doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg per day for 8 weeks)
Trial: 12574183
Drug: Troglitazone (Tgz)
DrugBank: Troglitazone (DB00197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Troglitazone (Tgz) 600 mg/d for 3 months
Trial: 3924065
Drug: Acipimox (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (750 mg/day)
Trial: 28117627
Drug: Manual-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual-based treatment for school refusal
Trial: 24347426
Drug: Raloxifene 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 120 mg/day for 1 month
Trial: 24347426
Drug: Estrogen (E₂)
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen (E₂) 4 mg/day for 1 month
Trial: 24347426
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment alone (0.5 mg/day) for 1 month
Trial: 24347426
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment with raloxifene (60 mg/day) for 1 month
Trial: 24347426
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment with estrogen (2 mg/day) for 1 month
Trial: 24347426
Drug: Raloxifene administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene administration
Trial: 21098449
Drug: varespladib 500
RxNorm normalized name: Varespladib
DrugBank: Varespladib (DB11909)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: varespladib 500 mg PO BID
Trial: 11025624
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cyproheptadine and propranolol
Trial: 1335645
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of live attenuated hepatitis A vaccine at doses of 10(4), 10(5), 10(6), and 10(7) TCID50
Trial: 1335645
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of live attenuated hepatitis A vaccine at doses of 10(6) and 10(7) TCID50
Trial: 6363896
Drug: Human (semisynthetic)
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human (semisynthetic) insulin
Trial: 27544023
Drug: Ahmed‐FP7 implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ahmed‐FP7 implant
Trial: 22221551
Drug: Sclerotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sclerotherapy with 75% glucose solution
Trial: 20929599
Drug: Extrafine BDP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extrafine BDP, 100 μg, b.i.d.
Trial: 20929599
Drug: Nonextrafine BDP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonextrafine BDP, 250 μg, b.i.d.
Trial: 19100092
Drug: Antiarrhythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drugs (AADs) for 3 months
Trial: 10774084
Drug: Baseline studies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline studies prior to randomisation to antimalarial prophylactic regimens
Trial: 6349608
Drug: Methazolamide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methazolamide (150 mg/d)
Trial: 2803090
Drug: Acetazolamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (500 mg/d)
Trial: 6349608
Drug: Methazolamide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methazolamide (100 mg/d) at low altitude
Trial: 28247654
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for acute serous and purulent pyelonephritis
Trial: 25579161
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia (G group)
Trial: 16183220
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel (10mg per day)
Trial: 10989855
Drug: Intramuscular laryngeal
RxNorm normalized name: LARYNGEAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular laryngeal electromyography
Trial: 1797191
Drug: 773U82.HCl at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 773U82.HCl at doses ranging from 15 mg/m2 to 980 mg/m2
Trial: 1797191
Drug: 773U82.HCl at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 773U82.HCl at 980 mg/m2
Trial: 1797191
Drug: 773U82.HCl at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 773U82.HCl at 720 mg/m2
Trial: 1797191
Drug: 773U82.HCl infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 773U82.HCl infusion duration increase
Trial: 6679239
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cost education and cost audits
Trial: 30669797
Drug: Control (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (2 ml normal saline)
Trial: 26012474
Drug: Nicorandil administration
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil administration after primary PCI
Trial: 23719148
Drug: Quality Improvement
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quality Improvement Tool - Pocket reminder card with preventive medication guidelines
Trial: 23719148
Drug: Quality Improvement
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quality Improvement Tool - Monthly team feedback reports
Trial: 8626882
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg COER-verapamil at 8:00 AM on an empty stomach, subjects remaining ambulatory
Trial: 8626882
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg COER-verapamil at 8:00 AM on an empty stomach, subjects remaining supine for 8 hours
Trial: 8626882
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg COER-verapamil at 10:00 PM with a standardized meal, subjects remaining supine for 8 hours
Trial: 8626882
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg COER-verapamil at 10:00 PM on an empty stomach, subjects remaining supine for 8 hours
Trial: 8626882
Drug: Time of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time of dosing
Trial: 2906457
Drug: roxatidine acetate
RxNorm normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxatidine acetate 75 mg
Trial: 2905253
Drug: roxatidine acetate
RxNorm normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxatidine acetate 150 mg
Trial: 2906457
Drug: roxatidine acetate
RxNorm normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxatidine acetate 300 mg
Trial: 2906457
Drug: roxatidine acetate
RxNorm normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxatidine acetate 600 mg
Trial: 352976
Drug: Chlorpromazine treatment
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpromazine treatment
Trial: 23376852
Drug: No adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjunctive treatment (control group II)
Trial: 20150572
Drug: Bevacizumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (both doses)
Trial: 19968384
Drug: CT +
RxNorm normalized name: Aveeno Protect + Hydrate SPF70 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT + pharmacotherapy
Trial: 16364575
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of trimegestone (TMG)
Trial: 15365734
Drug: roxithromycin 300
RxNorm normalized name: roxithromycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin 300 mg/OD for 6 weeks
Trial: 20642906
Drug: Bezafibrate 400
RxNorm normalized name: bezafibrate 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate 400 mg
Trial: 9365041
Drug: Immunohistochemistry using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunohistochemistry using QB monoclonal antibody
Trial: 1562863
Drug: 10, 20
RxNorm normalized name: Co-Q10, 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10, 20 or 30 mg/day of oral fluphenazine hydrochloride
Trial: 26768569
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment alternatives for Ebola virus, including repurposed drugs; specific dosages and durations not mentioned.
Trial: 25200552
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of vitamin D3 (250,000 IU) followed by oral maintenance vitamin D3/calcium (800 IU/500 mg)
Trial: 22455355
Drug: Ethanol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.25 g/kg)
Trial: 9800141
Drug: Ethanol and
RxNorm normalized name: Ethanol and glycine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol and Nitrous oxide (combination)
Trial: 8777409
Drug: Intracavernous injection
RxNorm normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernous injection of 10 mg moxisylyte
Trial: 6107678
Drug: 13‐cis retinoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13‐cis retinoic acid (0.1 mg‐1.0 mg/kg body‐weight)
Trial: 31304536
Drug: Ibrexafungerp 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrexafungerp 750 mg
Trial: 31304536
Drug: Ibrexafungerp 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrexafungerp 500 mg
Trial: 31304536
Drug: Micafungin (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin (continued therapy)
Trial: 27845219
Drug: Daily low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily low-dose tadalafil (5 mg)
Trial: 25877748
Drug: Platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based chemotherapy after gefitinib
Trial: 21219593
Drug: Cell phone-supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell phone-supported cognitive behavioural therapy (CBT) for anxiety disorders; specific dosage and duration not mentioned.
Trial: 20875374
Drug: Tapentadol IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol IR 100 mg
Trial: 19203298
Drug: Oxycodone HCl
RxNorm normalized name: oxycodone HCl
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone HCl IR 15 mg
Trial: 17893579
Drug: Lighter general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lighter general anesthesia (propofol 2 mug/mL and rimifentanil 2 ng/mL)
Trial: 17893579
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (propofol 4 microg/mL and rimifentanil 4 ng/mL)
Trial: 15321210
Drug: Bupivacaine 9.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 9.375 mg (15 ml of 0.0625%) with fentanyl 37.5 microg and adrenaline 37.5 microg
Trial: 15321210
Drug: Bupivacaine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 15 mg (15 ml of 0.1%) with fentanyl 30 microg and adrenaline 30 microg